Liberty Wealth Management LLC Acquires 167 Shares of Eli Lilly and Company (NYSE:LLY)

Liberty Wealth Management LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 11.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,586 shares of the company’s stock after acquiring an additional 167 shares during the quarter. Liberty Wealth Management LLC’s holdings in Eli Lilly and Company were worth $1,224,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Truvestments Capital LLC boosted its stake in Eli Lilly and Company by 19.1% in the 4th quarter. Truvestments Capital LLC now owns 673 shares of the company’s stock valued at $520,000 after purchasing an additional 108 shares during the period. Hopwood Financial Services Inc. bought a new stake in Eli Lilly and Company in the 4th quarter valued at $110,000. Farther Finance Advisors LLC boosted its stake in Eli Lilly and Company by 1.1% in the 4th quarter. Farther Finance Advisors LLC now owns 14,125 shares of the company’s stock valued at $10,904,000 after purchasing an additional 152 shares during the period. EverSource Wealth Advisors LLC boosted its stake in Eli Lilly and Company by 6.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 4,043 shares of the company’s stock valued at $3,121,000 after purchasing an additional 248 shares during the period. Finally, Sequoia Financial Advisors LLC boosted its stake in Eli Lilly and Company by 48.5% in the 4th quarter. Sequoia Financial Advisors LLC now owns 101,735 shares of the company’s stock valued at $78,539,000 after purchasing an additional 33,245 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Down 0.7 %

NYSE LLY opened at $823.95 on Wednesday. The business’s 50-day moving average price is $828.77 and its two-hundred day moving average price is $845.45. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The firm has a market capitalization of $781.25 billion, a PE ratio of 70.36, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its Board of Directors has approved a stock repurchase plan on Monday, December 9th that allows the company to buyback $15.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

Several equities analysts have weighed in on LLY shares. Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a report on Friday, January 17th. Morgan Stanley set a $1,146.00 price objective on Eli Lilly and Company in a report on Thursday, March 6th. Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a report on Thursday, January 16th. Wolfe Research started coverage on Eli Lilly and Company in a report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective for the company. Finally, Bank of America reaffirmed a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,009.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.